Genetic dissection of the psychotomimetic effects of cannabinoid exposure

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 52, Issue , 2014, Pages 33-40

  O'Tuathaigh, Colm M P ^a,b   Gantois, Ilse ^c   Waddington, John L ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b UNIVERSITY COLLEGE CORK   (Ireland)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Cannabis; Delta 9 tetrahydrocannabinol; Dopamine; Psychosis

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CANNABINOID; CANNABINOID 1 RECEPTOR; CATECHOL METHYLTRANSFERASE; ENDOCANNABINOID; NEU DIFFERENTIATION FACTOR; PROTEIN KINASE B; DOPAMINE; PSYCHEDELIC AGENT;

ARTICLE; BIOLOGICAL ACTIVITY; CANNABIS USE; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DOPAMINERGIC TRANSMISSION; ENVIRONMENTAL EXPOSURE; ENZYME ACTIVATION; GENE INTERACTION; GENETIC ANALYSIS; GENETIC SUSCEPTIBILITY; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; NONHUMAN; OUTCOME ASSESSMENT; PSYCHOSIS; PSYCHOTOMIMETIC EFFECT; REGULATORY MECHANISM; RISK FACTOR; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; ANIMAL; CANNABIS SMOKING; DRUG EFFECTS; GENE EXPRESSION; GENETIC PREDISPOSITION; GENETICS; METABOLISM;

ANIMALS; CANNABINOIDS; DOPAMINE; GENE EXPRESSION; GENETIC PREDISPOSITION TO DISEASE; HALLUCINOGENS; HUMANS; MARIJUANA SMOKING; PSYCHOTIC DISORDERS;

EID: 84899631385     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2013.11.002     Document Type: Article

References (120)

1. Alemany S., Arias B., Fatjó-Vilas M., Villa H., Moya J., Ibáñez M.I., et al. Psychosis-inducing effects of cannabis are related to both childhood abuse and COMT genotypes. Acta Psychiatr Scand 2013, (Feb 28, epub., in press).
2. Altar C.A., Cai N., Bliven T., Juhasz M., Conner J.M., Acheson A.L., et al. Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature 1997, 389:856-860.
3. Andersen S.L., Teicher M.H. Stress, sensitive periods and maturational events in adolescent depression. Trends Neurosci 2008, 31:183-191.
4. Arnone D., Barrick T.R., Chengappa S. Corpus callosum damage in heavy marijuana use: preliminary evidence from diffusion tensor tractography and tract-based spatial statistics. Neuroimage 2008, 41:1067-1074.
5. Arseneault L., Cannon M., Poulton R., Murray R., Caspi A., Moffitt T.E., et al. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ 2002, 325:1212-1213.
6. Arseneault L., Cannon M., Witton J., Murray R.M. Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry 2004, 184:110-117.
7. Ayhan Y., Sawa A., Ross C.A., Pletnikov M.V. Animal models of gene-environment interactions in schizophrenia. Behav Brain Res 2009, 204:274-281.
8. Batalla A., Soriano-Mas C., López-Solà M., Torrens M., Crippa J.A., Bhattacharyya S., et al. Modulation of brain structure by catechol-O-methyltransferase Val(158) Met polymorphism in chronic cannabis users. Addict Biol 2013, (Jan 14, epub., in press).
9. Bava S., Frank L.R., McQueeny T., Schweinsburg B.C., Schweinsburg A.D., Tapert S.F. Altered white matter microstructure in adolescent substance users. Psychiatry Res 2009, 173:228-237.
10. Beaulieu J.M., Sotnikova T.D., Marion S., Lefkowitz R.J., Gainetdinov R.R., Caron M.G. An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behaviour. Cell 2005, 122:261-273.
11. Beaulieu J.M., Tirotta E., Sotnikova T.D., Masri B., Salahpour A., Gainetdinov R.R., Borrelli E., Caron M.G. Regulation of Akt signaling by D2 and D3 dopamine receptors in vivo. J Neurosci 2007 Jan 24, 27(4):881-885.
12. Behan A.T., Hryniewiecka M., O'Tuathaigh C.M., Kinsella A., Cannon M., Karayiorgou M., et al. Chronic adolescent exposure to delta-9-tetrahydrocannabinol in COMT mutant mice: impact on indices of dopaminergic, endocannabinoid and GABAergic pathways. Neuropsychopharmacology 2012, 37:1773-1783.
13. Bhattacharyya S., Crippa J.A., Martin-Santos R., Winton-Brown T., Fusar-Poli P. Imaging the neural effects of cannabinoids: current status and future opportunities for psychopharmacology. Curr Pharm Des 2009, 15:2603-2614.
14. Bhattacharyya S., Morrison P.D., Fusar-Poli P. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 2010, 35:764-774.
15. Bhattacharyya S., Crippa J.A., Allen P., Martin-Santos R., Borgwardt S., Fusar-Poli P. Induction of psychosis by δ9-tetrahydrocannabinol reflects modulation of prefrontal and striatal function during attentional salience processing. Arch Gen Psychiatry 2012, 69:27-36.
16. Bhattacharyya S., Atakan Z., Martin-Santos R., Crippa J.A., Kambeitz J., Prata D., et al. Preliminary report of biological basis of sensitivity to the effects of cannabis on psychosis: AKT1 and DAT1 genotype modulates the effects of δ-9-tetrahydrocannabinol on midbrain and striatal function. Mol Psychiatry 2012, 17:1152-1155.
17. Bossong M.G., Jansma J.M., van Hell H.H. Effects of δ9-tetrahydrocannabinol on human working memory function. Biol Psychiatry 2012, 71:693-699.
18. Boucher A.A., Hunt G.E., Karl T., Micheau J., McGregor I.S., Arnold J.C. Heterozygous neuregulin 1 mice display greater baseline and delta(9)-tetrahydrocannabinol-induced c-Fos expression. Neuroscience 2007, 149:861-870.
19. Boucher A.A., Arnold J.C., Duffy L., Schofield P.R., Micheau J., Karl T. Heterozygous neuregulin 1 mice are more sensitive to the behavioural effects of delta9-tetrahydrocannabinol. Psychopharmacology (Berl) 2007, 192:325-336.
20. Boucher A.A., Hunt G.E., Micheau J., Huang X., McGregor I.S., Karl T., et al. The schizophrenia susceptibility gene neuregulin 1 modulates tolerance to the effects of cannabinoids. Int J Neuropsychopharmacol 2011, 14:631-643.
21. Burrows E.L., McOmish C.E., Hannan A.J. Gene-environment interactions and construct validity in preclinical models of psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35:1376-1382.
22. Caldú X., Vendrell P., Bartrés-Faz D., Clemente I., Bargalló N., Jurado M.A., et al. Impact of the COMT Val108/158 Met and DAT genotypes on prefrontal function in healthy subjects. Neuroimage 2007, 37:1437-1444.
23. Casadio P., Fernandes C., Murray R.M., Di Forti M. Cannabis use in young people: the risk for schizophrenia. Neurosci Biobehav Rev 2011, 35:1779-1787.
24. Caspi A., Moffitt T.E., Cannon M., McClay J., Murray R., Harrington H., et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene×environment interaction. Biol Psychiatry 2005, 57:1117-1127.
25. Chen J., Lipska B.K., Halim N., Ma Q.D., Matsumoto M., Melhem S., et al. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet 2004, 75:807-821.
26. Chen Y.W., Kao H.Y., Min M.Y., Lai W.S. A sex- and region-specific role of Akt1 in the modulation of methamphetamine-induced hyperlocomotion and striatal neuronal activity: implications in schizophrenia and methamphetamine-induced psychosis. Schizophr Bull 2013, (Mar 8, epub., in press).
27. Cohen M., Solowij N., Carr V. Cannabis, cannabinoids and schizophrenia: integration of the evidence. Aust N Z J Psychiatry 2008, 42:357-368.
28. Costas J., Sanjuán J., Ramos-Ríos R., Paz E., Agra S., Tolosa A., et al. Interaction between COMT haplotypes and cannabis in schizophrenia: a case-only study in two samples from Spain. Schizophr Res 2011, 127:22-27.
29. Coulston C.M., Perdices M., Tennant C.C. The neuropsychological correlates of cannabis use in schizophrenia: lifetime abuse/dependence, frequency of use, and recency of use. Schizophr Res 2007, 96:169-184.
30. De Chiara V., Angelucci F., Rossi S., Musella A., Cavasinni F., Cantarella C., et al. Brain-derived neurotrophic factor controls cannabinoid CB1 receptor function in the striatum. J Neurosci 2010, 30:8127-8137.
31. De la Serna E., Mayoral M., Baeza I. Cognitive functioning in children and adolescents in their first episode of psychosis: differences between previous cannabis users and nonusers. J Nerv Ment Dis 2010, 198:159-162.
32. Decoster J., van Os J., Kenis G., Henquet C., Peuskens J., De Hert M., van Winkel R. Age at onset of psychotic disorder: cannabis, BDNF Val66Met, and sex-specific models of gene-environment interaction. Am J Med Genet B Neuropsychiatr Genet 2011 Apr, 156B(3):363-369.
33. Decoster J., van Os J., Myin-Germeys I., De Hert M., van Winkel R. Genetic variation underlying psychosis-inducing effects of cannabis: critical review and future directions. Curr Pharm Des 2012, 18:5015-5023.
34. Delisi L.E., Bertisch H.C., Szulc K.U., majcher M., Brown K., Bappal A., et al. A preliminary DTI study showing no brain structural change associated with adolescent cannabis use. Harm Reduct J 2006, 3:17.
35. Desbonnet L., Waddington J.L., Tuathaigh C.M. Mice mutant for genes associated with schizophrenia: common phenotype or distinct endophenotypes?. Behav Brain Res 2009, 204:258-273.
36. Desbonnet L., O'Tuathaigh C., Clarke G., O'Leary C., Petit E., Clarke N., et al. Phenotypic effects of repeated psychosocial stress during adolescence in mice mutant for the schizophrenia risk gene neuregulin-1: a putative model of gene×environment interaction. Brain Behav Immun 2012, 26:660-671.
37. Doherty J.L., O'Donovan M.C., Owen M.J. Recent genomic advances in schizophrenia. Clin Genet 2012, 81:103-109.
38. D'Souza D.C., Perry E., MacDougall L., Ammerman Y., Cooper T., Wu Y.T., et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 2004, 29:1558-1572.
39. D'Souza D.C., Abi-Saab W.M., Madonick S., Forselius-Bielen K., Doersch A., Braley G. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry 2005, 57:594-608.
40. D'Souza D.C., Ranganathan M., Braley G., Gueorguieva R., Zimolo Z., Cooper T., et al. Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis. Neuropsychopharmacology 2008, 33:2505-2516.
41. D'Souza D.C., Pittman B., Perry E., Simen A. Preliminary evidence of cannabinoid effects on brain-derived neurotrophic factor (BDNF) levels in humans. Psychopharmacology (Berl). 2009 Mar, 202(4):569-578.
42. Egan M.F., Kojima M., Callicott J.H., Goldberg T.E., Kolachana B.S., Bertolino A., et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003, 112:257-269.
43. Eggan S.M., Lewis D.A. Immunocytochemical distribution of the cannabinoid CB1 receptor in the primate neocortex: a regional and laminar analysis. Cereb Cortex 2007, 17:175-191.
44. Eggan S.M., Mizoguchi Y., Stoyak S.R., Lewis D.A. Development of cannabinoid 1 receptor protein and messenger RNA in monkey dorsolateral prefrontal cortex. Cereb Cortex 2010, 20:1164-1174.
45. EMCDDA Annual Report 2010: The State of the Drugs Problemin Europe. Lisbon: European Monitoring Centre for Drugs and DrugAddiction (EMCDDA). 2010.
46. Estrada G., Fatjó-Vilas M., Muñoz M.J., Pulido G., Miñano M.J., Toledo E., et al. Cannabis use and age at onset of psychosis: further evidence of interaction with COMT Val158Met polymorphism. Acta Psychiatr Scand 2011, 123:485-492.
47. Fergusson D.M., Horwood L.J., Swain-Campbell N.R. Cannabis dependence and psychotic symptoms in young people. Psychol Med 2003, 33:15-21.
48. Freund T.F., Katona I., Piomelli D. Role of endogenous cannabinoids in synaptic signaling. Physiol Rev 2003, 83:1017-1066.
49. Gleason K.A., Birnbaum S.G., Shukla A., Ghose S. Susceptibility of the adolescent brain to cannabinoids: long-term hippocampal effects and relevance to schizophrenia. Transl Psychiatry 2012, 2:e199.
50. Gray L., Hannan A.J. Dissecting cause and effect in the pathogenesis of psychiatric disorders: genes, environment and behaviour. Curr Mol Med 2007, 7:470-478.
51. Grech A., Van Os J., Jones P.B., Lewis S.W., Murray R.M. Cannabis use and outcome of recent onset psychosis. Eur Psychiatry 2005, 20:349-353.
52. Gu Z., Jiang Q., Fu A.K., Ip N.Y., Yan Z. Regulation of NMDA receptors by neuregulin signaling in prefrontal cortex. J Neurosci 2005, 25:4974-4984.
53. Han S., Yang B.Z., Kranzler H.R., Oslin D., Anton R., Farrer L.A., Gelernter J. Linkage analysis followed by association show NRG1 associated with cannabis dependence in African Americans. Biol Psychiatry 2012 Oct 15, 72(8):637-644.
54. Harley M., Kelleher I., Clarke M., Lynch F., Arseneault L., Connor D., et al. Cannabis use and childhood trauma interact additively to increase the risk of psychotic symptoms in adolescence. Psychol Med 2009, 40:1627-1634.
55. Harrison P.J., Law A.J. Neuregulin 1 and schizophrenia: genetics, gene expression, and neurobiology. Biol Psychiatry 2006, 60:132-140.
56. Henquet C., Rosa A., Krabbendam L. An experimental study of catechol-o-methyltransferase Val158Met moderation of delta-9-tetrahydrocannabinol-induced effects on psychosis and cognition. Neuropsychopharmacology 2006, 31:2748-2757.
57. Ho B.C., Wassink T.H., Ziebell S., Andreasen N.C. Cannabinoid receptor 1 gene polymorphisms and marijuana misuse interactions on white matter and cognitive deficits in schizophrenia. Schizophr Res 2011, 128:66-75.
58. Houston J.E., Murphy J., Adamson G., Stringer M., Shevlin M. Childhood sexual abuse, early cannabis use, and psychosis: testing an interaction model based on the National Comorbidity Survey. Schizophr Bull 2008, 34:580-585.
59. Karayiorgou M., Simon T.J., Gogos J.A. 22q11.2.2 microdeletions: linking DNA structural variation to brain dysfunction and schizophrenia. Nat Rev Neurosci 2011, 11:402-416.
60. Karl T., Duffy L., Scimone A., Harvey R.P., Schofield P.R. Altered motor activity, exploration and anxiety in heterozygous neuregulin 1 mutant mice: implications for understanding schizophrenia. Genes Brain Behav 2007, 6:677-687.
61. Karl T., Burne T.H., Van den Buuse M., Chesworth R. Do transmembrane domain neuregulin 1 mutant mice exhibit a reliable sensorimotor gating deficit?. Behav Brain Res 2011, 223:336-341.
62. Kirby B.P., Waddington J.L., O'Tuathaigh C.M. Advancing a functional genomics for schizophrenia: psychopathological and cognitive phenotypes in mutants with gene disruption. Brain Res Bull 2010, 83:162-176.
63. Kuepper R., van Os J., Lieb R., Wittchen H.U., Henquet C. Do cannabis and urbanicity co-participate in causing psychosis? Evidence from a 10-year follow-up cohort study. Psychol Med 2011, 41:2121-2129.
64. Kvajo M., McKellar H., Gogos J.A. Avoiding mouse traps in schizophrenia genetics: lessons and promises from current and emerging mouse models. Neuroscience 2012, 211:136-164.
65. Lardinois M., Lataster T., Mengelers R., van Os J., Myin-Germeys I. Childhood trauma and increased stress sensitivity in psychosis. Acta Psychiatr Scand 2011, 123:28-35.
66. Law A.J., Wang Y., Sei Y., O'Donnell P., Piantadosi P., Papaleo F., et al. Neuregulin 1-ErbB4-PI3K signaling in schizophrenia and phosphoinositide 3-kinase-p110δ inhibition as a potential therapeutic strategy. Proc Natl Acad Sci U S A 2012, 109:12165-12170.
67. Leweke F.M., Piomelli D., Pahlisch F., Muhl D., Gerth C.W., Hoyer C., et al. Cannabidiol enhances anandamide signalling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2012, 2:e94.
68. Linszen D., van Amelsvoort T. Cannabis and psychosis: an update on course and biological plausible mechanisms. Curr Opin Psychiatry 2007, 20:116-120.
69. Løberg E.M., Hugdahl K. Cannabis use and cognition in schizophrenia. Front Hum Neurosci 2009, 3:53.
70. Long L.E., Chesworth R., Arnold J.C., Karl T. A follow-up study: acute behavioural effects of delta(9)-THC in female heterozygous neuregulin-1 transmembrane domain mutant mice. Psychopharmacology (Berl) 2010, 211:277-289.
71. Long L.E., Chesworth R., Huang X.F., Wong A., Spiro A., McGregor I.S., et al. Distinct neurobehavioural effects of cannabidiol in transmembrane domain neuregulin 1 mutant mice. PLoS One 2012, 7:e34129.
72. Long L.E., Chesworth R., Huang X.F., McGregor I.S., Arnold J.C., Karl T. Transmembrane domain Nrg1 mutant mice show altered susceptibility to the neurobehavioural actions of repeated THC exposure in adolescence. Int J Neuropsychopharmacol 2013, 16:163-175.
73. McGrath J., Welham J., Scott J. Association between cannabis use and psychosis-related outcomes using sibling pair analysis in a cohort of young adults. Arch Gen Psychiatry 2010, 67:440-447.
74. Medina K.L., Nagel B.J., Park A., McQueeny T., Tapert S.F. Depressive symptoms in adolescents: associations with white matter volume and marijuana use. J Child Psychol Psychiatry 2007, 48:592-600.
75. Moore T.H., Zammit S., Lingford-Hughes A., Barnes T.R., Jones P.B., Burke M., et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007, 370:319-328.
76. Moore S., Kelleher E., Corvin A. The shock of the new: progress in schizophrenia genomics. Curr Genomics 2011, 12:517-524.
77. Morrison P.D., Murray R.M. From real-world events to psychosis: the emerging neuropharmacology of delusions. Schizophr Bull 2009, 35:668-674.
78. Morrison P.D., Zois V., McKeown D.A., Lee T.D., Holt D.W., Powell J.F., et al. The acute effects of synthetic intravenous delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning. Psychol Med 2009, 39:1607-1616.
79. Murray R.M., Lappin J., Di Forti M. Schizophrenia: from developmental deviance to dopamine dysregulation. Eur Neuropsychopharmacol 2008, 18:S129-S134.
80. Newell K.A., Karl T., Huang X.F. A neuregulin 1 transmembrane domain mutation causes imbalanced glutamatergic and dopaminergic receptor expression in mice. Neuroscience 2013, 248:670-680.
81. O'Tuathaigh C.M., O'Sullivan G.J., Kinsella A., Harvey R.P., Tighe O., Croke D.T., et al. Sexually dimorphic changes in the exploratory and habituation profiles of heterozygous neuregulin-1 knockout mice. Neuroreport 2006, 17:79-83.
82. O'Tuathaigh C.M., Babovic D., O'Sullivan G.J., Clifford J.J., Tighe O., Croke D.T., et al. Phenotypic characterization of spatial cognition and social behavior in mice with 'knockout' of the schizophrenia risk gene neuregulin 1. Neuroscience 2007, 147:18-27.
83. O'Tuathaigh C.M., Hryniewiecka M., Behan A., Tighe O., Coughlan C., Desbonnet L., et al. Chronic adolescent exposure to δ-9-tetrahydrocannabinol in COMT mutant mice: impact on psychosis-related and other phenotypes. Neuropsychopharmacology 2010, 35:2262-2273.
84. O'Tuathaigh C.M., Harte M., O'Leary C., O'Sullivan G.J., Blau C., Lai D., et al. Schizophrenia-related endophenotypes in heterozygous neuregulin-1 'knockout' mice. Eur J Neurosci 2010, 31:349-358.
85. O'Tuathaigh C.M., Clarke G., Walsh J., Desbonnet L., Petit E., O'Leary C., et al. Genetic vs. pharmacological inactivation of COMT influences cannabinoid-induced expression of schizophrenia-related phenotypes. Int J Neuropsychopharmacol 2011, 15:1331-1342.
86. Papaleo F., Crawley J.N., Song J., Lipska B.K., Pickel J., Weinberger D.R., et al. Genetic dissection of the role of catechol-O-methyltransferase in cognition and stress reactivity in mice. J Neurosci 2008, 28:8709-8723.
87. Pelayo-Terán J.M., Pérez-Iglesias R., Mata I., Carrasco-Marín E., Vázquez-Barquero J.L., Crespo-Facorro B. Catechol-o-methyltransferase (COMT) Val158Met variations and cannabis use in first-episode non-affective psychosis: clinical-onset implications. Psychiatry Res 2010, 179:291-296.
88. Pelayo-Terán J.M., Suárez-Pinilla P., Chadi N., Crespo-Facorro B. Gene-environment interactions underlying the effect of cannabis in first episode psychosis. Curr Pharm Des 2012, 18:5024-5035.
89. Pistis M., Muntoni A.L., Pillolla G., Gessa G.L. Cannabinoids inhibit excitatory inputs to neurons in the shell of the nucleus accumbens: an in vivo electrophysiological study. Eur J Neurosci 2002, 15:1795-1802.
90. Potvin S., Joyal C.C., Pelletier J., Stip E. Contradictory cognitive capacities among substance-abusing patients with schizophrenia: a meta-analysis. Schizophr Res 2008, 100:242-251.
91. Quinn H.R., Matsumoto I., Callaghan P.D., Long L.E., Arnold J.C., Gunasekaran N., et al. Adolescent rats find repeated delta(9)-THC less aversive than adult rats but display greater residual cognitive deficits and changes in hippocampal protein expression following exposure. Neuropsychopharmacology 2008, 33:1113-1126.
92. Rabin R.A., Zakzanis K.K., George T.P. The effects of cannabis use on neurocognition in schizophrenia: a meta-analysis. Schizophr Res 2011, 128:111-116.
93. Rais M., Cahn W., Van Haren N., Schnack H., Caspers E., Hulshoff Pol H., et al. Excessive brain volume loss over time in cannabis-using first-episode schizophrenia patients. Am J Psychiatry 2008, 165:490-496.
94. Renard D., Taieb G., Gras-Combe G., Labauge P. Cannabis-related myocardial infarction and cardioembolic stroke. J Stroke Cerebrovasc Dis 2012, 21:82-83.
95. Reuter M., Peters K., Schroeter K., Koebke W., Lenardon D., Bloch B., et al. The influence of the dopaminergic system on cognitive functioning: a molecular genetic approach. Behav Brain Res 2005, 164:93-99.
96. Reuter M., Schmitz A., Corr P., Hennig J. Molecular genetics support Gray's personality theory: the interaction of COMT and DRD2 polymorphisms predicts the behavioural approach system. Int J Neuropsychopharmacol 2006, 9:155-166.
97. Roiser J.P., Stephan K.E., den Ouden H.E., Barnes T.R., Friston K.J., Joyce E.M. Do patients with schizophrenia exhibit aberrant salience?. Psychol Med 2009, 39:199-209.
98. Rubino T., Realini N., Braida D., Alberio T., Capurro V., Viganò D., Guidali C., Sala M., Fasano M., Parolaro D. The depressive phenotype induced in adult female rats by adolescent exposure to THC is associated with cognitive impairment and altered neuroplasticity in the prefrontal cortex. Neurotox Res. 2009 May, 15(4):291-302.
99. Schneider M., Koch M. Chronic pubertal, but not adult chronic cannabinoid treatment impairs sensorimotor gating, recognition memory, and the performance in a progressive ratio task in adult rats. Neuropsychopharmacology 2003, 28:1760-1769.
100. Schnell T., Koethe D., Daumann J., Gouzoulis-Mayfrank E. The role of cannabis in cognitive functioning of patients with schizophrenia. Psychopharmacology (Berl) 2009, 205:45-52.
101. Schubart C.D., Sommer I.E., van Gastel W.A. Cannabis with high cannabidiol content is associated with fewer psychotic experiences. Schizophr Res 2011, 130:216-221.
102. Solowij N., Michie P.T. Cannabis and cognitive dysfunction: parallels with endophenotypes of schizophrenia?. J Psychiatry Neurosci 2007, 32:30-52.
103. Spear L.P. The adolescent brain and age-related behavioral manifestations. Neurosci Biobehav Rev 2000, 24:417-463.
104. Spencer J.R., Darbyshire K.M., Boucher A.A., Kashem M.A., Long L.E., McGregor I.S., et al. Novel molecular changes induced by Nrg1 hypomorphism and Nrg1-cannabinoid interaction in adolescence: a hippocampal proteomic study in mice. Front Cell Neurosci 2013, 7:15.
105. Stefansson H., Sigurdsson E., Steinthorsdottir V., Bjornsdottir S., Sigmundsson T., Ghosh S., et al. Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet 2002, 71:877-892.
106. Stelzel C., Basten U., Montag C., Reuter M., Fiebach C.J. Effects of dopamine-related gene-gene interactions on working memory component processes. Eur J Neurosci 2009, 29:1056-1063.
107. Tan H.Y., Chen A.G., Kolachana B., Apud J.A., Mattay V.S., Callicott J.H. Effective connectivity of AKT1-mediated dopaminergic working memory networks and pharmacogenetics of anti-dopaminergic treatment. Brain 2012, 135:1436-1445.
108. Tanaka K.F., Ahmari S.E., Leonardo E.D., Richardson-Jones J.W., Budreck E.C., Scheiffele P., et al. Flexible accelerated STOP tetracycline operator-knockin (FAST): a versatile and efficient new gene modulating system. Biol Psychiatry 2010, 67:770-773.
109. Tosato S., Dazzan P., Collier D. Association between the neuregulin 1 gene and schizophrenia: a systematic review. Schizophr Bull 2005, 31:613-617.
110. Tunbridge E.M., Weinberger D.R., Harrison P.J. A novel protein isoform of catechol O-methyltransferase (COMT): brain expression analysis in schizophrenia and bipolar disorder and effect of Val158Met genotype. Mol Psychiatry 2006, 11:116-117.
111. van Os J., Bak M., Hanssen M., Bijl R.V., de Graaf R., Verdoux H. Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol 2002, 156:319-327.
112. van Os J., Rutten B.P., Poulton R. Gene-environment interactions in schizophrenia: review of epidemiological findings and future directions. Schizophr Bull 2009, 34:1066-1082.
113. van Os J., Kenis G., Rutten B.P. The environment and schizophrenia. Nature 2010, 468:203-212.
114. van Winkel R. Family-based analysis of genetic variation underlying psychosis-inducing effects of cannabis: sibling analysis and proband follow-up. Arch Gen Psychiatry 2011, 68:148-157. Genetic Risk and Outcome of Psychosis (GROUP) Investigators.
115. Verdejo-García A., Beatriz Fagundo A., Cuenca A., Rodriguez J., Cuyás E., Langohr K., et al. COMT val158met and 5-HTTLPR genetic polymorphisms moderate executive control in cannabis users. Neuropsychopharmacology 2013, 38:1598-1606.
116. Waddington J.L., Hennessy R.J., O'Tuathaigh C.M.P., Owoeye O., Russell V. Schizophrenia and the lifetime trajectory of psychotic illness: developmental neuroscience and pathobiology, redux. The origins of schizophrenia 2012, 3-21. Columbia University Press, New York. A.S. Brown, P.H. Patterson (Eds.).
117. Walss-Bass C., Raventos H., Montero A.P., Armas R., Dassori A., Contreras S., et al. Association analyses of the neuregulin 1 gene with schizophrenia and manic psychosis in a Hispanic population. Acta Psychiatr Scand 2006, 113:314-321.
118. Wegener N., Koch M. Behavioural disturbances and altered Fos protein expression in adult rats after chronic pubertal cannabinoid treatment. Brain Res 2009, 1253:81-91.
119. Yücel M., Bora E., Lubman D.I., Solowij N., Brewer W.J., Cotton S.M., et al. The impact of cannabis use on cognitive functioning in patients with schizophrenia: a meta-analysis of existing findings and new data in a first-episode sample. Schizophr Bull 2012, 38:316-330.
120. Zammit S., Owen M.J., Evans J., Heron J., Lewis G. Cannabis, COMT and psychotic experiences. Br J Psychiatry 2011, 199:380-385.